10 Hottest Small Cap Stocks to Buy Now
On November 12, Scott Chronert, Citi's U.S. equity strategist, appeared on a CNBC Television interview to discuss his bullish case for small- and mid-cap stocks.
Spyre Therapeutics Inc. (SYRE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 3,200,000 | $53,632,000 | 2.06% | |
| 2. | Braidwell LP Alex Karnal | 2,578,404 | $43,214,051 | 1.28% | |
| 3. | Driehaus Capital Richard Driehaus | 2,060,375 | $34,531,885 | -2% | 0.25% |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,988,084 | $33,320,288 | 1.63% | |
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 1,388,854 | $23,277,193 | 0.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.56 | 90,000 | $50,472.00 | 90,000 | 2022-08-25 | Filing | |
| $0.71 | 28,200 | $20,022.00 | 36,200 | 2022-06-08 | Filing | |
| $2.34 | 80,079 | $187,705.18 | 550,540 | 2022-03-16 | Filing | |
| $1.86 | 42,417 | $78,942.28 | 473,461 | 2022-03-15 | Filing | |
| $1.93 | 67,472 | $130,220.96 | 431,044 | 2022-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.66 | 16,845 | $398,552.70 | 701,907 | 2025-11-03 | Filing | |
| $23.13 | 28,155 | $651,225.15 | 718,752 | 2025-11-03 | Filing | |
| $16.26 | 18,428 | $299,639.28 | 97,994 | 2025-09-02 | Filing | |
| $36.76 | 6,700 | $246,312.77 | 27,360 | 2024-11-06 | Filing | |
| $36.43 | 300 | $10,929.00 | 34,060 | 2024-10-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,060,144 | $151,848,013 | 0.01% | |
| 2. | 4,018,101 | $67,343,373 | 6.06% | |
| 3. | 3,982,744 | $66,750,788 | 0% | |
| 4. | 3,621,996 | $60,704,653 | 0.75% | |
| 5. | 3,050,730 | $51,130,235 | 0% |
News See All
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial
On September 15, 2025, Spyre Therapeutics Inc. (NASDAQ:SYRE) announced the enrollment of the first patient in its Phase 2 SKYWAY trial targeting multiple autoimmune diseases.
10 Best Debt Free Small Cap Stocks to Buy Now
High leverage can be both an advantage and a liability.
Hedge Fund Resource Center Billionaire Hedge Funds
